31 Dec 2012, BioSpectrum Bureau , BioSpectrum
Singapore: BGI-Shenzhen (BGI) and Complete Genomics have obtained clearance from the Committee on Foreign Investment in the US (CFIUS) regarding BGI's proposed acquisition of Complete.
The clearance was pursuant to the previously announced agreement and plan of merger, dated September 15, 2012, among BGI, Beta Acquisition and Complete. BGI-Shenzhen had on December 14 extended the acquisition date to December 31, 2012.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers. Complete's financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins.